Form 4: CorMedix Director Alan W. Dunton Acquires 30,000 Stock Options
SEC Form 4 Filing
Alan W. Dunton, a director of CorMedix Inc., reported the acquisition of 30,000 stock options on March 5, 2024.
Summary
- On March 5, 2024, Alan W. Dunton, a director of CorMedix Inc., acquired 30,000 stock options.
- The options have an exercise price of $3.55.
- The options vest monthly over one year, contingent upon continued service on the board, and expire on March 5, 2034.
- Following the transaction, Dunton directly owns 30,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a routine grant of stock options to a director, which is a common practice.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Industry Context
This is a standard practice for companies to incentivize directors and align their interests with shareholders through stock option grants.
Stakeholder Impact
- The stock option grant aligns the director's interests with shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of earliest transaction: Alan W. Dunton acquired 30,000 stock options. |
| 03/05/2024 | Date of grant of options. |
| 03/05/2034 | Expiration date of the stock options. |
| 03/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.